TXMD - TherapeuticsMD, Inc.
0.88
-0.024 -2.727%
Share volume: 27,528
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations:
0.05%
PREVIOUS CLOSE
CHG
CHG%
$0.90
-0.02
-0.03%
Fundamental analysis
23%
Profitability
15%
Dept financing
15%
Liquidity
75%
Performance
20%
Performance
5 Days
-0.48%
1 Month
9.96%
3 Months
-20.00%
6 Months
-44.30%
1 Year
-59.07%
2 Year
-75.42%
Key data
Stock price
$0.88
DAY RANGE
$0.84 - $0.91
52 WEEK RANGE
$0.70 - $2.44
52 WEEK CHANGE
-$58.29
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
Company detail
CEO: Mark A. Glickman
Region: US
Website: therapeuticsmd.com
Employees: 420
IPO year: 2007
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: therapeuticsmd.com
Employees: 420
IPO year: 2007
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone. It also manufactures and distributes branded and generic prescription prenatal vitamins.
Recent news
TherapeuticsMD Full Year 2024 Earnings: US$0.20 loss per share (vs US$0.74 loss in FY 2023)
TherapeuticsMD ( NASDAQ:TXMD ) Full Year 2024 Results Key Financial Results Net loss: US$2.31m (loss narrowed by 70...
Read moreTherapeuticsMD Announces Full Year 2024 Financial Results
BOCA RATON, Fla., March 27, 2025--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2024.
Read more